Viewpoint Molecular Targeting
Coralville
About Viewpoint Molecular Targeting
Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $32.3M
- Funding stage: M&A
- Last round: Grant (Jan 2021)
- Website: viewpointmt.com
- Phone: (865) 356-1861
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Precision Medicine, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/viewpoint-molecular-targeting-47094 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.